Evidence map›Paper›PMID 40823023›Full record

ArticleFrontiers in nutrition2025

EAT-Lancet diet and risk of metabolic dysfunction-associated steatotic liver disease and other liver chronic diseases: a large prospective cohort study in the UK Biobank.

Shi-Yi Wu, Ya-Cong Bo, Ze-Yang Li, Xing-Yue Hu, Yang-Yang Ning, Jia Huang, Jun-Xi Zhang, Yong-Jian Zhu, Zeng-Li Yu, Hong-Yan Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shi-Yi Wu *Department of Medical Genetics, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, China.
Ya-Cong Bo *College of Public Health, Zhengzhou University, Zhengzhou, China.
Ze-Yang LiSchool of Public Health, Imperial College London, London, United Kingdom.
Xing-Yue HuDepartment of Medical Genetics, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, China.
Yang-Yang NingDepartment of Medical Genetics, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, China.
Jia HuangDepartment of Medical Genetics, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, China.
Jun-Xi ZhangNHC Key Laboratory of Birth Defects Prevention and Henan Key Laboratory of Population Defects Prevention, Zhengzhou, China.
Yong-Jian ZhuDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zeng-Li YuNHC Key Laboratory of Birth Defects Prevention and Henan Key Laboratory of Population Defects Prevention, Zhengzhou, China.
Hong-Yan LiuDepartment of Medical Genetics, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aim: As a newly recommended healthy dietary blueprint, the EAT-Lancet diet emphasizes both environmental sustainability and human health. However, its impact on chronic liver diseases remains unclear. This study examined the influence of the EAT-Lancet diet on the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and other chronic liver diseases. Methods: Our study included 160,394 UK Biobank participants who completed 24-h dietary assessments between April 2009 and June 2012, from which EAT-Lancet diet scores were calculated. The Cox proportional hazards models were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for the primary outcome (MASLD) and secondary endpoints, including cirrhosis, liver cancer, and other liver diseases. Results: A total of 1,727 cases of MASLD, 602 cases of liver cirrhosis, 103 cases of liver cancer, and 2,053 cases of other liver diseases were identified over a median follow-up period of 13.3 years. Using the lowest tertile as the reference, the highest EAT-Lancet diet index group demonstrated a 33% reduction in MASLD incidence (HR:0.67, multivariate 95%CI: 0.55, 0.80). In several secondary outcome measures, similar associations were also observed. Furthermore, the risk of MASLD was lowest among individuals with both higher EAT-Lancet dietary scores and lower genetic risk (HR = 0.52; 95%CI: 0.36-0.74), although no significant interaction was detected between the two groups. Conclusion: Adherence to the EAT-Lancet diet is associated with a reduced risk of chronic liver disease, independent of genetic factors.

Indexed as

chronic liver diseaseEAT-Lancet dietgene-diet interactionmetabolic dysfunction-associated steatotic liver diseasepolygenic risk score

Identifiers

PMID40823023
PMCPMC12350129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.